The vitreous pools beneath the retina, peeling it from the tissues where it is needed. Retinal detachment can be caused by holes in the retina or retinal tears, which allows the vitreous to leak through. Retinal detachment happens when the retina pulls away from its usual position at the back of the eye. However, the floaters may be present for other reasons such as eye inflammation due to allergies, bleeding inside the eye, or a systemic disease. Liquefying of the vitreous is a common part of aging. Floaters may indicate that the vitreous (the gel-like material connected loosely to the retina) is starting to liquefy. Floaters are typically black and can float in and out of vision. These reasons can include, but are not limited to, sudden injury, chronic illness, or the natural aging process.Ī floater is a cobweb, string, or speck that floats in the field of vision. Retinal damage may happen for a number of different reasons. If the retina becomes damaged, vision may be impaired as well. The retinal cells trigger nerve impulses that move between the optic nerve and the brain, where the visual images are created. This area contains light-sensitive cells. The retina is a layer that lies in the back part of the eye. For more information, call (310) 854-6201, or go to. In addition to its clinical services, Retina-Vitreous Associates provides continuing education and consulting services to the local, national and international ophthalmic communities and other healthcare industries. The physicians at Retina-Vitreous Associates are nationally recognized leaders in their field and participate in most clinical trials assessing new therapies for macular degeneration, diabetic retinopathy, as well as other retinal diseases. Retina-Vitreous Associates Medical Group specializes in the treatment of diseases affecting the retina, the vitreous and the macula. "This is a huge advance to treat such a sight debilitating disorder and one we're proud to be a part of." Boyer, MD, Senior Partner, Retina-Vitreous Associates Medical Group. "We are extremely pleased to offer our patients a non-surgical option to treat VMA," said David S. The breakdown of these proteins allows a better separation between the vitreous and macula and can reduce the chances that tugging will occur. JETREA is an enzyme that breaks down proteins in the eye responsible for VMA. The medication is injected into the patient's affected eye once as a single dose. The only other option to treat VMA is surgery, which is often reserved for patients at a time when possible irreversible damage is already done. Food and Drug Administration (FDA), approved JETREA as the first pharmacological agent for the treatment of VMA and became available to patients this week. This movement can lead to damage of the macula due to pulling or tugging on the macula. VMA can contribute to eye problems if the vitreous (jelly in the center of the eye) starts to move away from the macula (a part of the retina responsible for reading vision). Over a 1/4 million people in the US are affected by VMA a progressive, sight-threatening condition that, when left untreated, frequently leads to retinal distortion, further deterioration in vision, and irreversible damage to eyesight. 5, 2013 (GLOBE NEWSWIRE) - Retina-Vitreous Associates Medical Group, nationally recognized leaders that specialize in the treatment of diseases affecting the retina, are the first on the West Coast to offer their patients the much anticipated, JETREA, a new non-surgical treatment option for patients with Symptomatic Vitreomacular Adhesion (VMA), a retinal disorder that affects central vision.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |